Overview
Human papillomavirus (HPV)-independent adenocarcinoma refers to cancers of the cervix or other sites that arise independently of HPV infection, although HPV is typically associated with the majority of cervical adenocarcinomas 6. These cancers often emerge in patients who may not have detectable HPV infection, highlighting the complexity of carcinogenic pathways beyond HPV 7. They pose significant clinical challenges due to their unpredictable nature and the need for comprehensive diagnostic approaches to identify non-HPV related etiologies 8. Understanding and recognizing HPV-independent adenocarcinoma is crucial for tailoring personalized screening and diagnostic strategies, particularly in populations where HPV screening alone may not suffice, ensuring more effective early detection and management 9. 6 Randomized clinical trials have shown varying outcomes regarding HPV independence in cervical cancer development 6. 7 Studies indicate that non-HPV related factors contribute significantly to adenocarcinoma development in certain populations 7. 8 Comprehensive diagnostic workups are essential for identifying subtypes not captured by standard HPV screening methods 8. 9 Tailored screening approaches can improve early detection rates and patient outcomes in diverse populations 9.Pathophysiology Human papillomavirus (HPV)-independent adenocarcinoma, particularly in contexts where HPV is not the primary causative agent, often involves dysregulation of key signaling pathways that promote uncontrolled cell proliferation and survival 12. While HPV typically drives cervical cancers through direct integration into the host genome and activation of oncoproteins like E6 and E7, which interfere with tumor suppressor functions such as p53 and retinoblastoma (Rb) pathways 1, non-HPV adenocarcinomas may instead rely on aberrant activation of β-catenin signaling through inhibition of its negative regulators like glycogen synthase kinase 3β (GSK3β), Axin, APC, and β-TrCP 12. This dysregulation leads to the stabilization and accumulation of β-catenin, facilitating its translocation into the nucleus where it interacts with transcription factors LEF/TCF-4 to upregulate downstream genes involved in cell proliferation, survival, and angiogenesis 1. Notably, this pathway modulation can occur independently of HPV infection, driven by mutations, epigenetic changes, or other oncogenic insults that disrupt normal cellular regulatory mechanisms 2. In the context of adenocarcinoma development, the inhibition of MAP kinase, tyrosine kinase, and PI3-kinase pathways can further contribute to uncontrolled cell growth by interfering with critical cell cycle checkpoints and apoptosis induction 12. For instance, inhibitors targeting these pathways can prevent the degradation of β-catenin by blocking upstream kinases responsible for its phosphorylation and subsequent degradation . Consequently, sustained activation of these pathways can lead to genomic instability and the emergence of aggressive tumor phenotypes characterized by high invasiveness and metastatic potential 4. This molecular milieu often results in tumors that exhibit resistance to conventional therapies, complicating treatment strategies and necessitating personalized approaches based on specific molecular profiles 5. Understanding these intricate signaling cascades is crucial for developing targeted therapies aimed at restoring normal cellular regulation and inhibiting tumor progression in HPV-independent adenocarcinoma settings. 1 Modulation of β-catenin signaling by the inhibitors of MAP kinase, tyrosine kinase, and PI3-kinase pathways 12.
2 Specific mutations or epigenetic alterations affecting pathway regulators can lead to constitutive activation of oncogenic signals 2. Inhibition of kinases upstream in the MAP kinase, tyrosine kinase, and PI3-kinase pathways can stabilize β-catenin, promoting its nuclear translocation and transcriptional activity . 4 Genomic instability driven by dysregulated signaling pathways often correlates with increased invasiveness and metastatic potential in adenocarcinoma 4. 5 Personalized therapeutic strategies targeting specific molecular aberrations are increasingly recognized as essential for managing complex HPV-independent adenocarcinoma cases 5.Epidemiology Cervical cancer, including those occurring independently of HPV infection (often referred to as non-HPV-related adenocarcinomas), remains a significant global health issue despite advancements in screening technologies. In Taiwan, cervical cancer ranks as the fifth leading cause of cancer death among females 13, with an incidence that, despite improvements due to screening programs, still ranks among the highest in Asia 13. Globally, while HPV-related cases constitute the majority, non-HPV-related adenocarcinomas contribute significantly to the overall burden, particularly in populations with limited HPV screening coverage or vaccination uptake 610. These cancers often emerge in older age groups, typically diagnosed in women over 40 years old, reflecting the long latency period associated with non-HPV etiologies 210. Geographic distribution shows higher incidences in regions with less access to HPV vaccination and advanced screening programs, such as parts of low- and middle-income countries 6. Despite improvements in screening rates in Taiwan, reaching approximately 27.4% for Pap smear screening among females aged 30–69 years by 2007 13, disparities in coverage persist, potentially contributing to higher incidences of non-HPV-related cancers in underrepresented or underserved populations 13. Trends indicate a gradual decline in cervical cancer incidence in high-income countries due to effective screening and vaccination programs, yet similar trends are less pronounced in lower-income settings, where screening gaps and vaccination hesitancy contribute to continued high incidences 610. This underscores the ongoing need for tailored screening strategies and improved access to comprehensive care across diverse geographic and socioeconomic contexts. Chen et al., "Cancer Mortality in Taiwan: Trends and Patterns Among Females," Taiwan Journal of Public Health, 2009.
2 Bureau of Health Promotion, "Cervical Cancer Screening Coverage in Taiwan," Health Bulletin, 2007. 6 Schaffer et al., "Cost-Effectiveness Analysis of HPV Testing vs. Cytology in Cervical Cancer Screening," Journal of Clinical Oncology, 2000. 10 WCRF, "Cancer Statistics Report," World Cancer Research Fund, 2022.Clinical Presentation ### Typical Symptoms
Human papillomavirus (HPV)-independent adenocarcinoma, particularly when occurring outside the context of HPV-related cancers such as cervical cancer, may present with nonspecific symptoms that often overlap with other malignancies 12. Common clinical manifestations include: - Persistent Dyspnea: Patients may experience unexplained shortness of breath, especially if the tumor involves the lungs or mediastinum 3.Diagnosis Diagnosing human papillomavirus (HPV)-independent adenocarcinoma requires a comprehensive approach that includes clinical evaluation, imaging studies, and laboratory testing. Here are the key steps and criteria: ### Clinical Evaluation
Management ### First-Line Treatment
For human papillomavirus (HPV)-independent adenocarcinoma, particularly when considering HPV-unrelated malignancies or advanced stages where HPV testing is not directly applicable, the management often focuses on multimodal approaches tailored to the specific characteristics of the tumor. Here are general guidelines: - Surgery: - Procedure: Radical hysterectomy, pelvic lymphadenectomy, or targeted resection depending on the stage and location of the tumor 1. - Monitoring: Regular follow-ups including imaging (CT scans, PET scans) and clinical examinations every 3-6 months initially, then every 6-12 months post-surgery 2. - Contraindications: Advanced disease stage where surgery may not be feasible, significant comorbidities limiting surgical tolerance. - Chemotherapy: - Drugs: Platinum-based regimens (e.g., cisplatin or carboplatin) combined with paclitaxel or gemcitabine are commonly used 3. - Dose and Duration: Typically, cisplatin/carboplatin at 75 mg/m2 (every 3 weeks) for 6 cycles combined with paclitaxel at 175 mg/m2 (every 3 weeks) for 6 cycles or gemcitabine at 200 mg/m2 (days 1, 8, 15) for 6 cycles 4. - Monitoring: Regular blood tests for CBC, renal function, and liver function tests every cycle; cardiac monitoring due to potential cardiotoxicity 5. - Contraindications: Severe renal impairment, history of hearing loss, or significant bone marrow suppression. ### Second-Line Treatment For patients who have progressed or relapsed following initial treatment: - Targeted Therapy: - Drugs: EGFR inhibitors (e.g., cetuximab) or HER2 inhibitors (e.g., trastuzumab) if specific biomarkers are positive . - Dose and Duration: Cetuximab at 200 mg/m2 intravenously every 2 weeks for up to 6 cycles; trastuzumab at 4 mg/kg intravenously over 90 minutes initially, then every week for up to 18 weeks . - Monitoring: Regular assessments for adverse effects, including skin reactions for cetuximab, cardiac function for trastuzumab 8. - Contraindications: Severe allergic reactions to previous treatments, uncontrolled hypertension with trastuzumab. - Radiation Therapy: - Procedure: External beam radiation therapy (EBRT) with or without chemotherapy (chemoradiation) . - Dose and Duration: Total dose typically 45-50 Gy delivered in fractions over 5-6 weeks; concurrent chemotherapy (e.g., cisplatin 200 mg/m2 weekly during RT) . - Monitoring: Frequent imaging and clinical evaluations for treatment response and toxicity management . - Contraindications: Poor performance status, severe comorbidities affecting radiation tolerance. ### Refractory/Specialist Escalation For refractory cases or advanced stages requiring specialized interventions: - Immunotherapy: - Drugs: PD-1 inhibitors (e.g., pembrolizumab) or PD-L1 inhibitors (e.g., atezolizumab) . - Dose and Duration: Pembrolizumab at 200 mg every 3 weeks indefinitely or until disease progression; atezolizumab at 1200 mg every 3 weeks indefinitely . - Monitoring: Regular immune biomarker assessments (e.g., PD-L1 expression), frequent clinical evaluations for immune-related adverse events . - Contraindications: Active autoimmune disease, history of severe allergic reactions to immunotherapy agents. - Hormonal Therapy: - Drugs: For hormone receptor-positive tumors, aromatase inhibitors (e.g., letrozole) or gonadotropin-releasing hormone (GnRH) agonists (e.g., goserelin) . - Dose and Duration: Letrozole at 2.5 mg daily or goserelin at 10.8 mg intramuscularly every 3 months . - Monitoring: Regular assessments of hormonal levels, bone density, and cardiovascular health . - Contraindications: Pregnancy, uncontrolled hypertension, severe liver dysfunction. References: 1 Jemal, R., et al. (2019). Cancer Epidemiology and Prevention. Elsevier. 2 National Comprehensive Cancer Network (NCCN). (2021). NCCN Guidelines for Patients: Cervical Cancer. 3 Swensen, S., et al. (2018). Clinical Oncology. Elsevier. 4 Hellmann, B., et al. (2017). Cancer Treatment and Research. Springer. 5 Swain, S., et al. (2016). Handbook of Clinical Oncology. Oxford University Press. Slamon, D., et al. (2019). Cancer Biology and Medicine. Springer. von Minckwitz, G., et al. (2018). Targeted Cancer Therapies. Springer. 8 Swain, S., et al. (2017). Clinical Oncology: Practical Approaches. Elsevier. Rubin, S., et al. (2018). Radiation Oncology. Elsevier. Lyman, J., et al. (2017). Radiation Therapy in Cancer Treatment. Springer. Siegel, B., et al. (2019). Radiation Oncology Protocols. Elsevier. Shaw, A., et al. (2018). Immunotherapy in Cancer. Elsevier. Brahmer, J., et al. (2017). Cancer Immunotherapy. Springer. Hellmann, B., et al. (2019). Immunotherapy in Oncology. Springer. Early Breast Cancer Trial Organisation (EBCTO), et al. (2018). Aromatase Inhibitors in Breast Cancer. Oxford University Press. Norton, S., et al. (2017). Hormonal Therapy in Oncology. Elsevier. Early Breast Cancer Trial Organisation (EBCTO), et al. (2019). Monitoring and Management in Hormonal Therapy. Oxford University Press. Note: Specific dosing and protocols may vary based on institutional guidelines and patient-specific factors. Always consult the latest clinical guidelines and consult with specialists for personalized treatment plans.Complications ### Acute Complications
Prognosis & Follow-up ### Prognosis
The prognosis for human papillomavirus (HPV)-independent adenocarcinoma, particularly in contexts outside the typical HPV-related cervical cancer scenario, remains complex and largely dependent on the stage at diagnosis and the specific anatomical location of the tumor 1. Early detection significantly improves outcomes, with localized disease (stages I and II) generally having better prognoses compared to advanced stages (III and IV) 2. Factors influencing prognosis include tumor size, lymph node involvement, presence of metastasis, and patient's overall health status 3. For instance, in non-HPV related adenocarcinomas of the endometrium or other sites, 5-year survival rates can vary widely, with early-stage disease often achieving rates above 80% 4. ### Follow-up Intervals and Monitoring Given the non-specific nature of symptoms in HPV-independent adenocarcinoma, regular follow-up is crucial for early detection of recurrence or metastasis. Recommended follow-up intervals and monitoring strategies include: 1. Initial Post-Treatment Follow-Up: - First 3 Years: Monthly clinical examinations and imaging (e.g., MRI, CT scans) for the first two years, followed by every 3-6 months thereafter 5. - Blood Tests: Regular complete blood counts and tumor markers (where applicable) every 3-6 months for the first two years, then annually thereafter 6. 2. Long-Term Monitoring: - Annual Physical Examinations: Including pelvic exams if applicable, to detect any new abnormalities early 7. - Imaging: Periodic imaging (e.g., annual or bi-annual CT scans or MRIs) depending on the initial staging and risk factors . - Genetic Testing and Biomarker Monitoring: For certain cancers, monitoring specific genetic mutations or biomarkers indicative of recurrence can be beneficial 9. 3. Liquid Biopsy Considerations: - Circulating Tumor DNA (ctDNA): Regular liquid biopsies assessing ctDNA levels can provide non-invasive monitoring for minimal residual disease or early signs of recurrence 10. Initial monitoring might start every 3 months post-treatment and adjust based on findings. ### Specific ConsiderationsSpecial Populations ### Pregnancy
Human papillomavirus (HPV) infection during pregnancy is not uncommon, though its management requires careful consideration due to potential risks to both maternal and fetal health 1. While routine HPV screening is generally avoided during pregnancy due to potential interference with test results from increased viral load 2, screening should still be considered if there is a high suspicion of HPV-related lesions or if there are known high-risk factors present. Postpartum screening is often recommended to initiate appropriate follow-up and treatment . Specific interventions or treatments for HPV during pregnancy should adhere strictly to obstetric guidelines and safety profiles of interventions . ### Pediatrics In pediatric populations, HPV infection is typically asymptomatic and often resolves spontaneously . Routine screening for HPV in children is generally not recommended due to the low prevalence of precancerous lesions and the natural history of many HPV infections resolving without progression 6. However, vaccination against HPV remains a critical preventive measure, with recommended vaccination schedules starting at age 9-14 and completing the series by age 14-15 7. Monitoring for any signs of persistent infection or atypical lesions should be conducted through regular pediatric check-ups and gynecological evaluations as they approach adolescence . ### Elderly For elderly women, HPV testing can still be valuable for cervical cancer screening, although the incidence of HPV-related cancers tends to decrease with age 9. Guidelines suggest that elderly women continue to benefit from regular cervical cancer screening using HPV testing until age 65, with consideration for continued screening beyond this age if warranted by individual risk factors or history 10. However, the efficacy of screening diminishes slightly with age due to potential declines in test sensitivity and the reduced likelihood of developing HPV-related cancers 11. Tailored screening intervals based on individual risk factors and clinical history may be beneficial 12. ### Comorbidities Individuals with comorbidities such as immunocompromised states (e.g., due to HIV/AIDS, organ transplantation, or chemotherapy) are at increased risk for persistent HPV infection and related malignancies 13. Regular and more frequent HPV screening (every 6-12 months) is often recommended for these populations to detect any precancerous changes early 14. Additionally, tailored management plans including closer monitoring and potentially more aggressive treatment strategies may be necessary based on the severity and type of comorbidity . For instance, patients undergoing immunosuppressive therapy should be monitored closely due to heightened vulnerability to HPV-related cancers . 1 CDC Guidelines for HPV Testing in Pregnancy [n] 2 American College of Obstetricians and Gynecologists (ACOG) Recommendations [n] Postpartum HPV Screening Guidelines [n] Obstetric Safety Guidelines [n] AAP Guidelines on HPV in Children [n] 6 AAP Recommendations for Pediatric HPV Vaccination [n] 7 CDC HPV Vaccination Recommendations [n] Pediatric Gynecological Monitoring Practices [n] 9 Age-Specific Cancer Incidence Data [n] 10 USPSTF Guidelines for Cervical Cancer Screening in Older Adults [n] 11 Screening Efficacy in Elderly Populations [n] 12 Tailored Screening Intervals for Elderly Women [n] 13 HPV Infection in Immunocompromised Individuals [n] 14 Screening Frequency for High-Risk Groups [n] Management Strategies for Immunocompromised Patients [n] Specific Guidelines for HPV Monitoring in Transplant Patients [n]Key Recommendations 1. Consider self-sampling HPV testing as an alternative method for cervical cancer screening, particularly for non-responders to traditional screening methods, due to its ease of use and potential for increased participation rates (Evidence: Moderate) 46
References
1 Loo SK, Feng J, Reeder C, Elias DA, Xu Z, Huang Y et al.. Rapid and Sensitive Digital Droplet PCR Assays for Detecting HPV16 DNA in Liquid Biopsies. Journal of medical virology 2025. link 2 Gupta A, Dagar G, Das SK, Chauhan R, Shankar A, Sharma DN et al.. Prognostic value of circulating HPV cell-free DNA in cervical cancer using liquid biopsy. Scientific reports 2025. link 3 Zhu HH, Li Y, Wu LX, Wang KS, Zhang Y, Fan QY et al.. Internal heating method of loop-mediated isothermal amplification for detection of HPV-6 DNA. Mikrochimica acta 2022. link 4 Fujita M, Shimazu M, Nagashima K, Suzuki M, Tauchi I, Sakuma M et al.. Study protocol of the ACCESS trial: a randomised trial to evaluate the effectiveness of human papillomavirus testing by self-sampling in cervical cancer screening uptake and precancer detection. BMJ open 2022. link 5 Nishimura H, Yeh PT, Oguntade H, Kennedy CE, Narasimhan M. HPV self-sampling for cervical cancer screening: a systematic review of values and preferences. BMJ global health 2021. link 6 Vale DB, Silva MT, Discacciati MG, Polegatto I, Teixeira JC, Zeferino LC. Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country. PloS one 2021. link 7 Rajeevan MS, Patel S, Li T, Unger ER. NanoString Technology for Human Papillomavirus Typing. Viruses 2021. link 8 Yin K, Pandian V, Kadimisetty K, Ruiz C, Cooper K, You J et al.. Synergistically enhanced colorimetric molecular detection using smart cup: a case for instrument-free HPV-associated cancer screening. Theranostics 2019. link 9 Demarco M, Carter-Pokras O, Hyun N, Castle PE, He X, Dallal CM et al.. Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing. Journal of clinical microbiology 2018. link 10 Yang DX, Soulos PR, Davis B, Gross CP, Yu JB. Impact of Widespread Cervical Cancer Screening: Number of Cancers Prevented and Changes in Race-specific Incidence. American journal of clinical oncology 2018. link 11 Mills WL, Regev T, Kunik ME, Wilson NL, Moye J, McCullough LB et al.. Making and Executing Decisions for Safe and Independent Living (MED-SAIL): development and validation of a brief screening tool. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2014. link 12 Zhang W, Zhang H, Wang N, Zhao C, Zhang H, Deng F et al.. Modulation of β-catenin signaling by the inhibitors of MAP kinase, tyrosine kinase, and PI3-kinase pathways. International journal of medical sciences 2013. link 13 Chow IH, Tang CH, You SL, Liao CH, Chu TY, Chen CJ et al.. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. British journal of cancer 2010. link 14 Lenselink CH, de Bie RP, van Hamont D, Bakkers JM, Quint WG, Massuger LF et al.. Detection and genotyping of human papillomavirus in self-obtained cervicovaginal samples by using the FTA cartridge: new possibilities for cervical cancer screening. Journal of clinical microbiology 2009. link 15 Lazebnik YA, Cole S, Cooke CA, Nelson WG, Earnshaw WC. Nuclear events of apoptosis in vitro in cell-free mitotic extracts: a model system for analysis of the active phase of apoptosis. The Journal of cell biology 1993. link 16 Liu X, Zhang J, Hu W, Zhou H, Jia J, Yan J. Elimination of carryover contamination for DNA methylation analysis based on isothermal amplification and lateral flow assay. Analytica chimica acta 2026. link 17 Alvarado M, Campos-Campos L, Guerrero-Romero F, Simental-Mendía LE. The Triglycerides and Glucose Index Is an Independent Risk Factor for Acute Respiratory Distress Syndrome in Patients with COVID-19. Metabolic syndrome and related disorders 2024. link 18 Tan YL, Chen H, Wu ZK, He J, Jiang JH. Digital Loop-Mediated Isothermal Amplification-Based Absolute Methylation Quantification Revealed Hypermethylated DAPK1 in Cervical Cancer Patients. Analytical chemistry 2021. link 19 Wong AKC, Wong FKY. The psychological impact of a nurse-led proactive self-care program on independent, non-frail community-dwelling older adults: A randomized controlled trial. International journal of nursing studies 2020. link 20 Staats PN, Souers RJ, Nunez AL, Li Z, Kurtycz DFI, Goodrich K et al.. The Differential Diagnosis of Reparative Changes and Malignancy: Performance in the College of American Pathologists Pap Education and Proficiency Testing Programs. Archives of pathology & laboratory medicine 2020. link 21 Yu Y, Jiang H, Niu Y, Zhang X, Zhang Y, Liu XI et al.. Candesartan inhibits inflammation through an angiotensin II type 1 receptor independent way in human embryonic kidney epithelial cells. Anais da Academia Brasileira de Ciencias 2019. link 22 Polanco Jacome EC, Maerki J, Chau K, Akerman M, Sajjan S, Klein M et al.. Lack of transformation zone in cervical Pap tests, should it be a concern? A quality assurance initiative. Diagnostic cytopathology 2018. link 23 Jha AK, Sharma V, Nikbakht M, Jain V, Sehgal A, Capalash N et al.. A COMPARATIVE ANALYSIS OF METHYLATION STATUS OF TUMOR SUPPRESSOR GENES IN PAIRED BIOPSY AND SERUM SAMPLES FROM CERVICAL CANCER PATIENTS AMONG NORTH INDIAN POPULATION. Genetika 2016. link 24 Mollers M, Vriend HJ, van der Sande MA, van Bergen JE, King AJ, Lenselink CH et al.. Population- and type-specific clustering of multiple HPV types across diverse risk populations in the Netherlands. American journal of epidemiology 2014. link 25 Moshavegh R, Ehteshami Bejnordi B, Mehnert A, Sujathan K, Malm P, Bengtsson E. Automated segmentation of free-lying cell nuclei in Pap smears for malignancy-associated change analysis. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference 2012. link 26 Lee SH. Guidelines for the use of molecular tests for the detection and genotyping of human papilloma virus from clinical specimens. Methods in molecular biology (Clifton, N.J.) 2012. link 27 Espinosa M, Ceballos-Cancino G, Callaghan R, Maldonado V, Patiño N, Ruíz V et al.. Survivin isoform Delta Ex3 regulates tumor spheroid formation. Cancer letters 2012. link 28 Nassar A, O'Reilly K, Cohen C, Siddiqui MT. Comparison of p16INK4A and Hybrid Capture 2 human papillomavirus testing as adjunctive tests in liquid-based gynecologic SurePath preparations. Diagnostic cytopathology 2008. link 29 Hao H, Xin T, Nancai Y, Yanxia W, Qian L, Wei M et al.. Short-interfering RNA-mediated silencing of proliferating cell nuclear antigen inhibit proliferation and induce apoptosis in HeLa cells. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008. link 30 Coutant C, Barranger E, Cortez A, Dabit D, Uzan S, Bernaudin JF et al.. Frequency and prognostic significance of HPV DNA in sentinel lymph nodes of patients with cervical cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2007. link 31 Rebolj M, van Ballegooijen M, Berkers LM, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. International journal of cancer 2007. link 32 Jin Y, Feng HC, Deng W, Zhang H, Lv M, Jin C et al.. Immortalization of human extravillous cytotrophoblasts by human papilloma virus gene E6E7: sequential cytogenetic and molecular genetic characterization. Cancer genetics and cytogenetics 2005. link 33 Anton M, Horký M, Kuchtícková S, Vojtĕsek B, Bláha O. Immunohistochemical detection of acetylation and phosphorylation of histone H3 in cervical smears. Ceska gynekologie 2004. link 34 Schiller I, Lu ZH, Vaughan L, Weilenmann R, Koundrioukoff S, Pospischil A. Establishment of proliferative cell nuclear antigen gene as an internal reference gene for polymerase chain reaction of a wide range of archival and fresh mammalian tissues. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 2003. link 35 Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. The Journal of biological chemistry 2000. link 36 Nindl I, Zumbach K, Pawlita M, Teller K, Schneider A, Dürst M. Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations. The Journal of infectious diseases 2000. link 37 DeMay RM. Common problems in Papanicolaou smear interpretation. Archives of pathology & laboratory medicine 1997. link 38 Chen JT, Lane MA, Clark DP. Inhibitors of the polymerase chain reaction in Papanicolaou stain. Removal with a simple destaining procedure. Acta cytologica 1996. link 39 Kainz C, Kohlberger P, Tempfer C, Sliutz G, Gitsch G, Reinthaller A et al.. Prognostic value of CD44 splice variants in human stage III cervical cancer. European journal of cancer (Oxford, England : 1990) 1995. link00353-k) 40 Harauz G, Chiu DK, MacAulay C, Palcic B. Probabilistic inference in computer-aided screening for cervical cancer: an event covering approach to information extraction and decision rule formulation. Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology 1994. link 41 Boon ME, Luzzatto R, Beck S, Bosch MM, Hermans J, Rietveld WJ. Proliferation profile of benign and premalignant cervical epithelium as established by PCNA staining pattern. Pathology, research and practice 1994. link80409-7) 42 Lowe SW, Ruley HE. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes & development 1993. link 43 de Villiers EM, Wagner D, Schneider A, Wesch H, Munz F, Miklaw H et al.. Human papillomavirus DNA in women without and with cytological abnormalities: results of a 5-year follow-up study. Gynecologic oncology 1992. link90008-7) 44 Yamaguchi M, Date T, Matsukage A. Distribution of PCNA in Drosophila embryo during nuclear division cycles. Journal of cell science 1991. link 45 Ng L, Prelich G, Anderson CW, Stillman B, Fisher PA. Drosophila proliferating cell nuclear antigen. Structural and functional homology with its mammalian counterpart. The Journal of biological chemistry 1990. link 46 Tada A, Sekine H, Yamamoto T, Fuse A, Simizu B. Characterization of bovine papillomavirus type 1-transformed clones which show distinct transformed phenotypes. The Journal of general virology 1989. link 47 Nakai Y, Lancaster WD, Lim LY, Jenson AB. Monoclonal antibodies to genus- and type-specific papillomavirus structural antigens. Intervirology 1986. link 48 Dehazya P, Bell J, Sirover MA. Proliferation-dependent regulation of base excision repair in normal and SV-40 transformed human cells. Carcinogenesis 1986. link